By embracing diversity in #ClinicalTrials, we enable more equitable and inclusive healthcare. How can this be achieved? Swipe right to learn more.
Boehringer Ingelheim
Arzneimittelherstellung
Ingelheim am Rhein, Rhineland-Palatinate 1.808.631 Follower:innen
Info
Seit mehr als 135 Jahren erforscht, entwickelt und produziert Boehringer Ingelheim neue Medikamente mit hohem therapeutischem Nutzen für Mensch und Tier. Als Pharmaunternehmen in Familienbesitz planen wir langfristig und investieren daher besonders in die Forschung und Entwicklung. Wir sind stolz, so einige der größten Gesundheitsprobleme unserer Zeit angehen zu können. Unsere Vision „Werte schaffen durch Innovation“ hat unsere Zusammenarbeit seit jeher geprägt und ist für uns Anspruch und Antrieb zugleich. Mit Hauptsitz in Ingelheim, Deutschland, beschäftigt Boehringer Ingelheim weltweit insgesamt rund 53.000 Mitarbeiter. Weitere Informationen zu Boehringer Ingelheim finden Sie unter www.boehringer-ingelheim.de
- Website
-
http://www.boehringer-ingelheim.com
Externer Link zu Boehringer Ingelheim
- Branche
- Arzneimittelherstellung
- Größe
- 10.001 Beschäftigte
- Hauptsitz
- Ingelheim am Rhein, Rhineland-Palatinate
- Art
- Privatunternehmen
- Spezialgebiete
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals und Contract Manufacturing
Orte
Beschäftigte von Boehringer Ingelheim
-
Gwen Whitfield Foster
-
Thomas Macauley
Research Data Management - Lab Services Engineer at Boehringer-Ingelheim
-
Mitchell Taub
Highly Distinguished Research Fellow
-
Ralf Schundelmeier
Product Leader (ex Salesforce) - Building Platforms for Applications, GenAI / Machine Learning & Data
Updates
-
We're not only driving innovation ourselves, we're also sharing open source technologies and device development knowledge with others. In order to improve retinal health monitoring we're sharing our software and to best involve patients in device development we provide our blueprint. Want to know more about our approach? Explore here: https://bit.ly/3XicGXt #PatientCentricity #HealthcareInnovation #KnowledgeSharing
-
#NEWS: The German Vice Chancellor and Federal Minister of Economics Robert Habeck visited our new biomass power plant in Ingelheim today. By using renewable sources, the plant supplies up to 95% of our site's energy needs. This will save around 50,000 tons of CO₂ per year in the future. Learn more about the inauguration and our #sustainability goals: https://bit.ly/3S1dtIS #GreenEnergy
-
Disparities in clinical trials must become a thing of the past. Inclusion of race, sex, age, genetics, demographics and geographies in clinical trial designs allows us to achieve relevant healthcare solutions that meet the needs of diverse patient populations. Read more here: https://lnkd.in/erYSU5db #ClinicalTrials #Diversity
-
#NEWS: Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics, is moving to the next phase in clinical development. Based on the positive data from our first clinical studies and the switch to an improved antibody we aim to provide innovative immuno-oncology treatments to the benefit of more people. Learn more: https://bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment
-
“Vision is more than just a function, it’s the sense that people most value, it connects individuals to their way of life.” Read more from our Director of Cardio-Metabolic Diseases Research/Retinal Health, Remko Bakker, as he reflects on our research and development program in #RetinalHealth 👉 https://lnkd.in/eb5YN9Pj
-
It's essential to raise awareness of the impact that diseases like generalized pustular psoriasis (#GPP) have on people's lives. By collaborating with patient organizations like IFPA, we aim to support their efforts to empower people living with GPP.
Generalized Pustular Psoriasis #GPP is a rare, severe form of #psoriaticdisease. Today Emmylou Casanova shared her experience navigating painful symptoms and finding a diagnosis. On stage with Prof Ricardo Romiti who stressed the need for continuous patient care. Register to watch online: https://lnkd.in/dRJDbMMh. Presented by Boehringer Ingelheim at #IFPAConference2024.
-
#HCP: Tango is a dance in which 2 people communicate through their movements. In the same way, it also takes 2 tests to get the full picture about #ChronicKidneyDisease (CKD). Follow clinical guidelines from diabetes and kidney organizations and issue 2 tests – an eGFR (blood) and UACR (urine) test. Learn more here: https://lnkd.in/eHhyKVMc
-
Together with the Advisory Board on Cat Diseases (ABCD) we proudly recognize Dr. Katharina Zwicklbauer (Ludwig-Maximilians-Universität München) with the 2024 Young Scientist Award. Katharina's research on feline infectious peritonitis (FIP), a fatal disease caused by a feline coronavirus, that mostly affects young cats, made important contributions to the field of feline medicine. Just three years ago, there were no treatment options available. Now, there is a whole new product class that we still need to fully explore. In her controlled study, Katharina evaluated different oral formulations of these new antivirals and showed promising results on the clinical evolution and virological parameters. #LifeForward
-
#NEWS: We're launching the Phase 1 study of BI 3034701, a potential first-in-class, triple agonist obesity treatment developed in our partnership with Gubra. Discover how we are advancing our comprehensive strategy at https://bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation